PROVISIONAL PROGRAMME
(contents subject to change)
Loews Coronado Bay Resort, San Diego, USA
5 to 7 December 2025
(on-demand access available until 4 March 2026)

FRIDAY 5 DECEMBER

SESSION 1 JOINT OPENING SESSION	
08.30 – 08.35	Welcome **– A Al-Chalabi (UK) and B Dickie (UK)**
08.35 – 08.45	Welcome from The ALS Association – **C Balas (USA)**
08.45 – 09.25	**Stephen Hawking Memorial Lecture:** Space-induced human neural senescence – ***A Muotri (USA)***
09.25 – 09.45	International Alliance Forbes Norris Award
09.45 – 10.00	IPG Award and winner's research presentation

10.00 – 10.30 COFFEE

SESSION 2A MODELLING AND TREATING ALS WITH STEM CELLS	SESSION 2B GENES AND PHENOTYES
10.30 – 11.00 Introduction: Opportunities and challenges ***C Svendsen (USA)*** ***M Cudkowicz (USA)***	**10.30 – 11.15** Genetics and phenotypic heterogeneity of ALS/MND in Central and South America ***JM Matamala (Chile)*** ***M Franca (Brazil)***
11.00 – 11.20 Lessons learned from therapeutic stem cell trials ***J Glass (USA)***	**11.15 – 11.30** Penetrance of neurodegenerative disorders in families carrying C9orf72 repeat expansions ***A Douglas (UK)***
11.20 – 11.40 Use of advanced CRISPR technologies in iPSC modelling ***C Clelland (USA)***	**11.30 – 11.45** Phenome-wide association study of C9orf72 pathogenic repeat expansions using ICD-10 diagnosis codes in the UK Biobank ***A Soma (UK)***
11.40 – 12.00 Organoid and assembloid models to study neurodegenerative disease ***J Andersen (USA)***	**11.45 – 12.00** Short tandem repeat expansions as genetic risk factors and disease modifiers in ALS ***K-Y Jih (Taiwan)***
12.00 – 12.30 **DISCUSSION**	**12.00 – 12.15** Incidence of neurodegenerative diseases in c9orf72 expansion carriers is influenced by UNC13A genotype ***J Gao (UK)***
	12.15 – 12.30 Genotype-phenotype analysis of TARDBP p.M337V in a large Chinese ALS family: An 18-year follow up story ***M Deng (China)***

12.30 – 14.00 LUNCH

SESSION 3A GENETICS AND GENOMICS	SESSION 3B CLINICAL TRIALS AND TRIAL DESIGN
14.00 – 14.15 A new cause of familial ALS: Loss of function of DNAJC7 impairs TDP-43 regulation ***T Yamashita (Japan)***	**14.00 – 14.15** DNL343 in ALS: Results from the double-blind placebo-controlled, randomized HEALEY ALS Platform Trial ***S Babu (USA)***
14.15 – 14.30 Large-scale exome analysis reveals novel rare variant contributions to ALS and identifies YKT6 and ARPP21 as risk genes ***K Kenna (Netherlands)***	**14.15 – 14.30** Clinical results of a Phase 2a trial evaluating the synaptogenic small molecule SPG302 in ALS participants ***D Rowe (Australia)***
14.30 – 14.45 Characterization and functional evaluation of RNA-driven gene fusions in ALS ***A Boudi (USA)***	**14.30 – 14.45** Top line results of the Phase 2 proof-of-concept study of AP-101, a first in class human antibody targeting misfolded SOD1 in ALS ***A Genge (Canada)***
14.45 – 15.00 Developmental, oxidative stress-associated clonal somatic mutations in sporadic ALS ***H Kim (South Korea)***	**14.45 – 15.00** From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 clinical and biomarker insights into a global Phase 3 trial ***M Cudkowicz (USA)***
15.00 – 15.15 Recurrent patterns of widespread neuronal genomic damage shared by major neurodegenerative disorders ***Z Zhou (USA)***	**15.00 – 15.15** Top line results of the Phase 1b, open label, multiple ascending dose study of VRG50635 in participants with familial and sporadic ALS ***L van den Berg (Netherlands)***
15.15 – 15.30 Unravelling TDP-43 pathology in ALS: A spatially resolved multiomics approach ***Z Butti (USA)***	**15.15 – 15.30** Phenotypic heterogeneity and ALS/MND subtypes: Potential impact on ALS research and clinical trial design ***J Rosenfeld (USA)***

15.30 – 16.00 COFFEE

SESSION 4A CELL AND ORGANELLE ANALYSES	SESSION 4B CLINICAL ELECTROPHYSIOLOGY AND IMAGING
16.00 – 16.30 Imaging protein aggregation in neurodegenerative disease ***D Klenerman (UK)***	**16.00 – 16.30** ALS through a physiologist's prism: Possible contributions of motor neuron circuit pathophysiology ***R Brownstone (USA)***
16.30 – 17.00 Organellomics: AI-driven deep organelle phenotyping uncovers novel ALS mechanisms in motor neurons ***E Hornstein (Israel)***	**16.30 – 16.45** Spinal motoneuron excitability as a marker of upper motor neuron dysfunction in Primary Lateral Sclerosis ***M Oliveira Santos (Portugal)***
17.00 – 17.15 Project Genesis: A program on the origins of sporadic ALS. Nucleoporin coding variants cause altered nuclear pore structure, function, downstream TDP-43 dysfunction and neurodegeneration in sporadic ALS ***J Rothstein (USA)***	**16.45 – 17.00** Application of automated brain segmentation software (Quantib) in a cohort of patients affected by amyotrophic lateral sclerosis ***A Doretti (Italy)***
17.15 – 17.30 Novel cell specific insights from single-cell multiome profiling of diseased and healthy motor cortex ***J Cooper-Knock (UK)***	**17.00 – 17.15** ALS cervical cord MRI metanalysis shows flattening of the cervical enlargement region ***T Yazdanian (USA)***
	17.15 – 17.30 Multiparametric MRI neuroimaging reveals widespread brain alterations in ALS beyond the motor cortex ***S Ghaderi (Iran)***

17.30 – 19.00 - POSTER SESSION A

SATURDAY 6 DECEMBER

SESSION 5A EPIGENETICS, AGING AND SELECTIVE VULNERABILITY	SESSION 5B COGNITIVE AND PSYCHOLOGICAL ASSESSMENT AND SUPPORT	SESSION 5C PRIMARY LATERAL SCLEROSIS
08.30 – 09.00 The genome and its memory: Epigenetic studies of ALS and related diseases ***E Rogaeva (Canada)***	**08.30 – 09.00** Clinical management and cognitive testing in ALS and Frontotemporal Spectrum Disorder ***C Lomen-Hoerth (USA)***	***DETAILS TBC***
09.00 – 09.15 Integrated transcriptomic and epigenetic profiling in ALS motor neurons using ONT direct RNA and DNA sequencing ***J Melki (Australia)***	**09.00 – 09.20** Survival, cognitive and behavioural impairment in ALS ***R Radakovic (UK)***	
09.15 – 09.30 Neuronal aging leads to mislocalization of TDP-43 ***K Rhine (USA)***	**09.20 – 09.40** Characterising behavioural symptoms in ALS: The ECAS Extended Behaviour interview ***C McHutchinson (UK)***	
09.30 – 09.45 Regional susceptibility to TDP-43 pathology is driven independently by age and disease specific factors ***H Spence (UK)***	**09.40 – 10.00** Exploring the role of relationship closeness in the association between behavioural symptoms and carers' anticipatory grief in MND ***A Trucco (UK)***	
09.45 – 10.00 Adenosine deaminase loss leads to purine metabolism dysfunction, senescence and reduced DNA repair mechanisms in sALS astrocytes ***S Allen (UK)***		

10.00 – 10.30 COFFEE

SESSION 6A PROTEOSTASIS & PROTEOTOXICITY	SESSION 6B BIOMARKERS	SESSION 6C EPIDEMIOLOGY
10.30 – 11.00 Disease mechanisms and therapeutic strategies in TDP-43 proteinopathies ***D Cleveland (USA)***	**10.30 – 10.50** Proteomic analysis of cerebrospinal fluid identified two distinct molecular subtypes in ALS ***P Lingor (Germany)***	**10.30 – 10.50** The incidence and prevalence of ALS among people with diabetes mellitus are increasing in the United States ***X Song (USA)***
11.00 – 11.15 AP21A and the autophagy pathway modify TDP-43 toxicity ***A Held (USA)***	**10.50 – 11.10** Characterising the CSF biomarker signature of Calpain-2 activity in ALS and the biomarker impact of Calpain-2 inhibition in a preclinical model of ALS ***R Bowser (USA)***	**10.50 – 11.10** Association of military branch and rank with ALS incidence among United States veterans ***M Weisskopf (USA)***
11.15 – 11.30 A disease-responsive modified cyclin F gene therapy for clearance of cytoplasmic TDP-43 ***J Davidson (Australia)***	**11.10 – 11.30** A blood test to monitor TDP-43 dysfunction for ALS ***P Wong (USA)***	**11.10 – 11.30** How pre-diagnosis comorbidities shape ALS prognosis in a large Chinese cohort ***M Deng (China)***
11.30 – 11.45 TDP-43 oligomer-specific antibody detects misfolded TDP-43 in ALS and rescues phenotype in ALS iPSC-derived neurons and mouse models ***Y-R Chen (Taiwan)***	**11.30 – 11.45** Blood-derived miRNA signature accurately diagnoses ALS ***R Dunlop (USA)***	**11.30 – 11.50** Extreme exercise in males is linked to onset of ALS in C9orf72 ***G Erdi-Krausz (UK)***

11.45 – 12.00 Novel TDP-43 aptamers identify early aggregation events in C9orf72 mutant human motor neurons ***O Taso (UK)***	**11.45 – 12.00** Combination of serum neurofilament light chain and cardiac troponin T as biomarkers improves diagnostic accuracy in ALS ***P Lindenborn (Germany)***	**11.50 – 12.10** Another brick in our knowledge of ALS causes: A population-based study of residential clustering ***A Calvo (Italy)***
12.00 – 12.15 Mutation-dependent stress pathway activation in ALS: Insights from VAPB P56S motor neurons ***H Miranda (USA)***	**12.00 – 12.15** Neurodegeneration NULISA panel in ALS patients and presymptomatic subjects reveals potential diagnostic and prognostic biomarkers: A premodiALS study ***L Tzeplaeff (Germany)***	**12.10 – 12.30** The International ALS/MND Natural History Consortium: Co-ordination, data quality, compliance, sustainability and sharing ***A Sherman (USA)***
12.15 – 12.30 Macrophage migration inhibitory factor (MIF) as a potential therapeutic target for ALS ***A Israelson (Israel)***	**12.15 – 12.30** Skin as a window to central TDP-43 pathology in ALS ***K Hanna (UK)***	

12.30 – 14.00 LUNCH

SESSION 7A RNA BIOLOGY	SESSION 7B ALS-FTD PATHOGENESIS	SESSION 7C NUTRITIONAL & RESPIRATORY MANAGEMENT
14.00 – 14.30 Regulation of RNA processing in neuronal health, aging and disease ***G Yeo (USA)***	**14.00 – 14.30** FTD/ALS pathogenesis: swimming upstream ***W Seeley (USA)***	**14.00 – 14.20** Optimised machine learning for time-to-event prediction in healthcare applied to timing of gastrostomy in ALS: A multi-centre, retrospective model development and validation study ***M Weinreich (UK)***
14.30 – 14.45 RNA-binding protein mislocalization in ALS and FTLD ***A Breevoort (USA)***	**14.30 – 15.00** Contribution of C9orf72 loss of function to ALS and FTD ***J Robertson (Canada)***	**14.20 – 14.40** Weight trajectories and survival following PEG insertion in patients with MND at a single site university affiliated hospital: A retrospective cohort study ***M Joyce (Australia)***
14.45 – 15.00 Elucidating the pathological interplay between cytoskeletal alterations and mRNA metabolism in Profilin 1-mutant human motor neurons ***C Steffke (Germany)***	**15.00 – 15.15** TDP-43 toxic gain of function links ALS, FTD and Alzheimer's disease through splicing dysregulation ***W Van Zuiden (Israel)***	**14.40 – 15.00** Prevalence and clinical relevance of gastrointestinal symptoms in ALS: A prospective observational study ***J Lops (Italy)***
15.00 – 15.15 The ribonucleoprotein complex of ALS-associated circular RNA hsa_circ_0000119 harbors key proteins linked to ALS pathophysiology ***K Smith (USA)***	**15.15 – 15.30** Contribution of Alzheimer's disease co-pathology to cognitive impairment in ALS: Evidence from cerebrospinal fluid, blood plasma and autopsy data ***E Kasper (Germany)***	**15.00 – 15.15** Oral Secretion Scale: A multi-national validated clinimetric scale for assessing state of secretion management in NIV-treated ALS patients identifies differences in secretion management device and medication use according to site of onset ***P Cazzolli (USA)***
15.15 – 15.30 TYK2 mediates neuroinflammation in brains with cytoplasmic dsRNA co-inciding with TDP-43 pathology: A common therapeutic approach for neurodegenerative diseases ***L König (USA)***		**15.15 – 15.30** Deep learning-derived chest CT metrics predict disease progression and survival in ALS ***J Kim (South Korea)***

15.30 – 16.00 COFFEE

SESSION 8A DISEASE MODELS	SESSION 8B PRECLINICAL AND PRODROMAL ALS	SESSION 8C IMPROVING CLINICAL DECISION MAKING: RESEARCH, POLICY AND PRACTICE
16.00 – 16.20 An elongator mouse model of ALS spotlights TDP-43 in the motor neuron nucleolus ***L George (USA)***	**16.00 – 16.15** Applying machine learning in predictive multiomics reveals biomarkers of an ALS prodrome ***A Strange (UK)***	**16.00 – 16.15** Oligogenic risk and emerging genetic modifiers: Hot topics in genetic counselling and testing for ALS/FTD ***K Salmon (Canada)***
16.20 – 16.40 C9orf72 dipeptide repeat proteins affect spinal motor neuron selective vulnerability and impact neuronal plasticity in knock-in mouse models ***C Milioto (UK)***	**16.15 – 16.30** Spatial transcriptomics identifies distinct peripheral immune signatures in pre-symptomatic ALS ***J Gregory (UK)***	**16.15 – 16.30** ALS VUS Second Opinion Service (VUS SOS): assisting the world's clinicians with VUS annotations and interpretation ***M Harms***
16.40 – 17.00 Neuronal targeted Caveolin-1 overexpression preserves mitochondrial integrity and cognitive function in a TDP-43 mouse model of ALS/FTD ***V Ta (USA)***	**16.30 – 16.45** ALS and FTD have distinct prediagnostic blood biochemical profiles ***C Chalitsos (UK)***	**16.30 – 16.45** Red Flags for ALS referral: Insights from the Turin ALS Expert Center ***A Chiò (Italy)***
17.00 – 17.15 Deciphering metabolic dysregulation at the synapse in drosophila models of ALS ***S Langberg (USA)***	**16.45 – 17.00** Predicting phenoconversion to clinically manifest disease: results of a large-scale proteomic study ***M Benatar (USA)***	**16.45 – 17.00** Characteristics and early diagnosis on MND in 67 million individuals in England: A comparative study on phenotyping models derived by AI, Knowledge Graph and the MND Association Red Flags tool ***Y Abdulle (UK)***
17.15 – 17.30 Novel strategies to prevent aberrant central motor synapse elimination in ALS-FTD ***M Van Campenhoudt (Switzerland)***	**17.00 – 17.15** Higher blood total cholesterol, LDL-c and HDL-c all associated with increased risk of ALS up to ten years prior to diagnosis: A nationwide multiple registry case-control study ***J Storgaard (Denmark)***	**17.00 – 17.15** Remote speech-derived biomarkers enable sensitive and feasible longitudinal monitoring of ALS progression ***A König (Germany)***
	17.15 – 17.30 Hypermetabolism is common among symptomatic and asymptomatic C9orf72 pathogenic variant carriers and is associated with elevated neurofilament light chain levels ***I Lee (USA)***	**17.15 – 17.30** Early prediction of bulbar decline in ALS using remotely-collected objective speech measures: A Kaplan-Meier time-to-event analysis ***A Ramanarayanan (USA)***

17.30 – 19.00 POSTER SESSION B

SUNDAY 7 DECEMBER

08.30 – 10.00 POSTER SESSION C

10.00 – 10.30 COFFEE

SESSION 9A FUS ALS	SESSION 9B THERAPEUTIC STRATEGIES	SESSION 9C ASSISTIVE TECHNOLOGY
10.30 – 10.50 Dissecting the role of skeletal muscle in FUS-associated ALS ***H Walgrave (Netherlands)***	**10.30 – 11.00** Machine learning enabled ALS target and therapeutic discovery ***S Sances (USA)***	**10.30 – 11.00** Enhancing quality of life through insights based on the ALS/MND Personal Needs Matrix ***J Chudge (UK)***
10.50 – 11.10 RNA aptamers enable selective detection of FUS pathology in ALS ***F Waldron (UK)***	**11.00 – 11.15** Development of ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, for the treatment of ALS ***S Reda (USA)***	**11.00 – 11.30** Transforming communications for ALS patients: Clinical Validation of an AI-powered augmented reality brain-computer Interface ***C Ullrich (USA)***
11.10 – 11.30 Targeting aberrant FUS intron retention in ALS ***Y Wang (UK)***	**11.15 – 11.30** Development of a novel brain-penetrant small molecule for rectifying TDP-43 dysfunction in ALS ***A Berson (USA)***	**11.30 – 12.00** The Triple 'A' Framework: Expanding access to AAC for people with ALS/MND ***J Schorey (USA)***
11.30 – 11.50 M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development ***T Shelkovnikova (UK)***	**11.30 – 11.45** Development of LTX-002, a novel ASO for the treatment of ALS ***L Heckman (USA)***	**12.00 – 12.20** **DISCUSSION**
11.50 – 12.10 Identifying FUS-like sporadic ALS patients through molecular phenotypic profiling ***S Altschuler (USA)***	**11.45 – 12.00** Nonclinical studies supporting the clinical development of the antisense oligonucleotide TRCN-1023 to restore UNC13A protein and function in people living with ALS ***I Antonijevic (USA)***	
12.10 – 12.30 Longitudinal profiling of transcriptomic and proteomic changes in biofluids of FUS-ALS patients treated with FUS antisense oligonucleotide ***O Rifai (USA)***	**12.00 – 12.15** AAV-delivered Anti-PC-OxPL antibody fragments: A novel therapeutic strategy targeting ALS pathology ***A Duarte (USA)***	
	12.15 – 12.30 Impact of intrathecal delivery of INS1202 AAV9-SOD1-shRNA on hallmarks of neurodegeneration in a murine disease model of ALS and patient-derived in vitro models ***L Ferraiuolo (USA)***	

12.20 – 13.30 LUNCH

SESSION 10 JOINT CLOSING SESSION	
13.30 – 13.40	Invitation to Amsterdam 2026
13.40 – 13.50	Poster Prizes
13.50 – 14.00	Healey Center Award
14.00 – 14.10	Lalji Prize
14.10 – 14.40	Advances in SMA treatment: Lessons for ALS – ***C Sumner (USA)***
14.40 – 15.10	***S Gleason (USA)***
15.10 – 15.20	Late breaking news